Effect of prior therapy on tumor mutational burden in NSCLC

BACKGROUND: Higher tumor mutation burden (TMB) in advanced non-small cell lung cancer (NSCLC) is associated with superior outcomes with checkpoint inhibitor therapy. Tissue samples subject to TMB analysis may be acquired after DNA-damaging therapies such as chemotherapy or radiation. The impact of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonna, Sushma, Vanderwalde, Ari, Nieva, Jorge, Poorman, Kelsey Anne, Saul, Michelle, von Buttlar, Xinyu, Hu, John Y., Liu, Stephen V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044473/
https://www.ncbi.nlm.nih.gov/pubmed/33889505
http://dx.doi.org/10.21037/tlcr-20-1076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044473/
https://www.ncbi.nlm.nih.gov/pubmed/33889505
http://dx.doi.org/10.21037/tlcr-20-1076

Ejemplares similares